Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis (Q37889119)

24 August 2017

1 reference

title

Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis (English)

1 reference

24 August 2017

0 references

5

John P Bilezikian

1 reference

24 August 2017

2

Natalie E Cusano

1 reference

24 August 2017

4

Serge Cremers

1 reference

24 August 2017

Aline G Costa

1

1 reference

24 August 2017

Barbara C Silva

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

14 June 2011

1 reference

Nature Reviews Rheumatology

24 August 2017

published in

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

447-456

1 reference

Genomic organization and chromosome localization of the human cathepsin K gene (CTSK)

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The regulation of cathepsin K gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Autocatalytic activation of human cathepsin K.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Biosynthesis and processing of cathepsin K in cultured human osteoclasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K expression in human lung.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Human osteoblasts produce cathepsin K.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K mRNA and protein expression in prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Identification of cathepsin K as a novel marker of adiposity in white adipose tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Expression and regulation of cathepsin K in skin fibroblasts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The collagenolytic activity of cathepsin K is unique among mammalian proteinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Biochemical properties and regulation of cathepsin K activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The gene for pycnodysostosis maps to human chromosome 1cen–q21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Craniosynostosis in pycnodysostosis: broadening the spectrum of the cranial flat bone abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

A novel missense mutation in cathepsin K (CTSK) gene in a consanguineous Pakistani family with pycnodysostosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Molecular analysis of a novel cathepsin K gene mutation in a Chinese child with pycnodysostosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Pycnodysostosis. Clinical and genetic considerations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

THE MALADY OF TOULOUSE-LAUTREC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Bone density, strength, and formation in adult cathepsin K (-/-) mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K: boon or bale for atherosclerotic plaque stability?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Pivotal role of cathepsin K in lung fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K and the design of inhibitors of cathepsin K.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K inhibitors: a novel target for osteoporosis therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Bisphosphonates: a review of their pharmacokinetic properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Pharmacology of bisphosphonates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Peptidomimetic inhibitors of cathepsin K.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Drug-induced morphea: report of a case induced by balicatib and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Effect of cathepsin k inhibitor basicity on in vivo off-target activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.77

The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21670768

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

2 cases of a condensing osseous disease: pynodysostosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21670768

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21670768

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2011.77

1 reference

24 August 2017

1 reference